Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Apixaban Solution vs Tablets
NCT02034565Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2010
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in venous thromboembolism (VTE) and stroke (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time at 72 hours and 1 more. Started Feb 2010; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)stroke
Beyond the preview
Go deeper on NCT02034565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034565.